Previous 10 | Next 10 |
Therapy Demonstrated Safety, Stabilization/Shrinkage of Treated Tumors Expanded Development for Monotherapy and Combination Therapy Anticipated ATLANTA, GA - ( NewMediaWire ) - January 04, 2024 - GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology co...
2024-01-02 16:23:19 ET More on GeoVax GeoVax Labs, Inc. (GOVX) Q3 2023 Earnings Call Transcript Seeking Alpha’s Quant Rating on GeoVax Historical earnings data for GeoVax Financial information for GeoVax For further details see: GeoVax Labs...
ATLANTA, GA, Dec. 27, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire - GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that David Dodd, Chief Executive Officer, will present at the Bi...
ATLANTA, GA, Dec. 19, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that it has amended a previously executed Patent and Biological M...
80% Survival in Nonhuman Primates Observed in a Lethal Challenge Model ATLANTA, GA, Nov. 30, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, ...
ATLANTA, GA - ( NewMediaWire ) - November 29, 2023 - GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that its senior management will participate in two upcoming investor events: ...
Presentation of Data from Phase 2 Open-Label Study of GEO-CM04S1 Next-Generation COVID-19 Vaccine Demonstrates Potent Antibody and Cellular Immunity in Immunocompromised Patients ATLANTA, GA, Nov. 28, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs,...
Single-Dose Protection Demonstrated Against Multiple SARS-CoV-2 Variants ATLANTA, GA, Nov. 14, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, to...
2023-11-09 09:51:10 ET More on GeoVax GeoVax Labs, Inc. (GOVX) Q3 2023 Earnings Call Transcript Seeking Alpha’s Quant Rating on GeoVax Historical earnings data for GeoVax Financial information for GeoVax For further details see: GeoVax GAAP...
2023-11-08 21:26:03 ET GeoVax Labs, Inc. (GOVX) Q3 2023 Earnings Conference Call November 08, 2023, 04:30 PM ET Company Participants Max Gadicke - Stern, IR David Dodd - Chairman and CEO Mark Reynolds - CFO Kelly McKee - Chief Medical Officer Conference...
News, Short Squeeze, Breakout and More Instantly...
ATLANTA, GA - ( NewMediaWire ) - July 11, 2024 - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines against cancer and infectious diseases, today announced that it has entered into a definitive securities purchase agreement with a cert...
GeoVax Labs, Inc. (NASDAQ: GOVX) is one of today's top gainers. The company's shares have moved 20.05% on the day to $3.02. GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and cancers using modified vaccinia ank...
Award of BARDA Project NextGen contract represents a significant milestone event; total value of award to GeoVax and its CRO partner total approximately $367-388 million BARDA-funded 10,000-participant Phase 2b study will evaluate and compare GeoVax’s ...